Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune
connective-tissue disease. Once considered an untreatable and unpredictable condition …

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Fibrosis is defined as an excessive deposition of connective tissue components and can
affect virtually every organ system, including the skin, lungs, liver and kidney. Fibrotic tissue …

Rheumatoid arthritis (RA) is a systemic inflammatory disorder, with the most common extra-
articular manifestation of RA being lung involvement. While essentially any of the lung …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Background Systemic sclerosis is a connective tissue disease characterised by multiorgan
fibrosis with an autoimmune background and poor prognosis. Although a few drugs have …

Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …

Summary Background In the Safety and Efficacy of Nintedanib in Systemic Sclerosis
(SENSCIS) trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in …